News – Page 1154 – Endpoints News

SIGN UP

Pfizer launching first US mAb biosimilar with Remicade knockoff, but you can forget about any fire sale

9 years ago

Vertex snares $75M windfall in revised CFF deal; Ex-Celgene R&D prez Daniel starts advisory group

9 years ago

Sofinnova bags $650M for a dedicated biotech fund

9 years ago

PTC shares plunge anew after FDA slaps down Duchenne drug for a second time

9 years ago

Safety threat forces FDA to put a hold on Regeneron, Teva’s big NGF pain drug fasinumab

9 years ago

Clinton campaign staff: "We have started the war with pharma!!"

9 years ago

Now with actual data in hand, Celgene touts an early response for Crohn’s drug mongersen

9 years ago

Powerful Dems orchestrated campaign at FDA to provide Biogen drug to a dying, high-profile fundraiser

9 years ago

Flex Pharma's cramp study fails, shares plunge; FDA makes Egalet wait on pain drug

9 years ago

Sarepta lands a valuable priority review voucher on Exondys 51 OK

9 years ago

Post-merger, gene therapy player Adverum makes Amber Salzman CEO, delays a clinical trial start

9 years ago

Boehringer-Ingelheim has some explaining to do; It's time biotech came to grips with compassion

9 years ago

Biotechs grabbed $1.83B in VC cash in Q3. Still fast but a little less furious

9 years ago

FDA's controversial OK for eteplirsen spurs second thoughts for a rejected rival at BioMarin

9 years ago

NeuroVive shares crater on PhII flop; F-Prime contributes $7.5M in startup cash for Akriveia

9 years ago

The compassionate use poll: A lopsided vote favors posting policies, with plenty of fretting

9 years ago

Tesaro v Myriad: Niraparib partners squared off in court as Tesaro tried to quash a contrary press release

9 years ago

Merck KGaA: This time we’ve got our R&D act together (seriously)

9 years ago

TG Therapeutics maps a shortcut to the FDA with lead drug for CLL

9 years ago

Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea

9 years ago

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

9 years ago

Adaptimmune looks to salvage ovarian cancer study by adding fludarabine to prep patients

9 years ago

AzurRx clips its IPO price, but manages to get the job done

9 years ago

Tiny RXi bags an option to buy CAR-T fledgling MirImmune

9 years ago

First page Previous page 1151 1152 115311541155 1156 1157 Next page Last page